Becton, Dickinson (BDX) Q3 results: Revenues: $4,350M (+1.7%); Medical: $2,311M (+2.9%); Life Sciences: $1,058M (-1.9%); Interventional: $981M (+2.8%).
Net Income: $413M (-25.7%); EPS: $1.51 (-25.6%); Non-GAAP EPS: $3.08 (+5.8%); CF Ops: $1,959M (+25.7%).
Fiscal 2019 Guidance: Revenue growth (reported basis): 8% – 9% (unch); Non-GAAP EPS: $11.65 – 11.75 (unch).
Previously: Becton, Dickinson EPS beats by $0.02, misses on revenue (Aug. 6)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.